Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination?
In Japan, healthcare workers (HCWs) are vaccinated against measles, rubella, chickenpox, mumps, and hepatitis B to prevent nosocomial infection; however, some do not produce sufficient antibodies (“suboptimal responders”). This study compared immune responses to a severe acute respiratory syndrome c...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/14/5/956 |
| _version_ | 1827665928005877760 |
|---|---|
| author | Wataru Ogura Kouki Ohtsuka Sachiko Matsuura Takahiro Okuyama Satsuki Matsushima Satoko Yamasaki Hiroyuki Miyagi Kumiko Sekiguchi Hiroaki Ohnishi Takashi Watanabe |
| author_facet | Wataru Ogura Kouki Ohtsuka Sachiko Matsuura Takahiro Okuyama Satsuki Matsushima Satoko Yamasaki Hiroyuki Miyagi Kumiko Sekiguchi Hiroaki Ohnishi Takashi Watanabe |
| author_sort | Wataru Ogura |
| collection | DOAJ |
| description | In Japan, healthcare workers (HCWs) are vaccinated against measles, rubella, chickenpox, mumps, and hepatitis B to prevent nosocomial infection; however, some do not produce sufficient antibodies (“suboptimal responders”). This study compared immune responses to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 mRNA) vaccine among HCWs with normal and suboptimal responses to conventional vaccines. In this prospective cohort study, 50 HCWs received two doses of BNT162b2 mRNA vaccine 3 weeks apart. SARS-CoV-2 anti-spike antibodies were measured 11 times, starting before the first vaccination and ending 5 months after the second vaccination. Antibody titers of four suboptimal and 46 normal responders were compared. SARS-CoV-2 neutralizing antibody activity was measured twice in suboptimal responders, 1 week/1 month and 5 months after the second vaccination. The SARS-CoV-2 anti-spike antibody was detectable in the samples from suboptimal and normal responders at each timepoint after vaccination. Suboptimal responders exhibited SARS-CoV-2 neutralizing antibody activity 1 week/1 month as well as 5 months after the second vaccination; however, activity was slightly reduced at 5 months. Our findings show that suboptimal responders do acquire adequate SARS-CoV-2 anti-spike and SARS-CoV-2 neutralizing antibodies from vaccination to prevent SARS-CoV-2. SARS-CoV-2 mRNA vaccines should thus be recommended for both normal and suboptimal responders to conventional vaccines. |
| first_indexed | 2024-03-10T01:37:51Z |
| format | Article |
| id | doaj.art-d5d3fcabce4146d9972b5782d233034d |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-10T01:37:51Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-d5d3fcabce4146d9972b5782d233034d2023-11-23T13:30:54ZengMDPI AGViruses1999-49152022-05-0114595610.3390/v14050956Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination?Wataru Ogura0Kouki Ohtsuka1Sachiko Matsuura2Takahiro Okuyama3Satsuki Matsushima4Satoko Yamasaki5Hiroyuki Miyagi6Kumiko Sekiguchi7Hiroaki Ohnishi8Takashi Watanabe9Department of Clinical Laboratory, Kyorin University Hospital, Mitaka, Tokyo 181-8611, JapanDepartment of Laboratory Medicine, Kyorin University School of Medicine, Mitaka, Tokyo 181-8611, JapanDepartment of Clinical Laboratory, Kyorin University Hospital, Mitaka, Tokyo 181-8611, JapanDepartment of Clinical Laboratory, Kyorin University Hospital, Mitaka, Tokyo 181-8611, JapanDepartment of Laboratory Medicine, Kyorin University School of Medicine, Mitaka, Tokyo 181-8611, JapanDepartment of Laboratory Medicine, Kyorin University School of Medicine, Mitaka, Tokyo 181-8611, JapanDepartment of Clinical Laboratory, Kyorin University Hospital, Mitaka, Tokyo 181-8611, JapanDepartment of Clinical Laboratory, Kyorin University Hospital, Mitaka, Tokyo 181-8611, JapanDepartment of Laboratory Medicine, Kyorin University School of Medicine, Mitaka, Tokyo 181-8611, JapanDepartment of Laboratory Medicine, Kyorin University School of Medicine, Mitaka, Tokyo 181-8611, JapanIn Japan, healthcare workers (HCWs) are vaccinated against measles, rubella, chickenpox, mumps, and hepatitis B to prevent nosocomial infection; however, some do not produce sufficient antibodies (“suboptimal responders”). This study compared immune responses to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 mRNA) vaccine among HCWs with normal and suboptimal responses to conventional vaccines. In this prospective cohort study, 50 HCWs received two doses of BNT162b2 mRNA vaccine 3 weeks apart. SARS-CoV-2 anti-spike antibodies were measured 11 times, starting before the first vaccination and ending 5 months after the second vaccination. Antibody titers of four suboptimal and 46 normal responders were compared. SARS-CoV-2 neutralizing antibody activity was measured twice in suboptimal responders, 1 week/1 month and 5 months after the second vaccination. The SARS-CoV-2 anti-spike antibody was detectable in the samples from suboptimal and normal responders at each timepoint after vaccination. Suboptimal responders exhibited SARS-CoV-2 neutralizing antibody activity 1 week/1 month as well as 5 months after the second vaccination; however, activity was slightly reduced at 5 months. Our findings show that suboptimal responders do acquire adequate SARS-CoV-2 anti-spike and SARS-CoV-2 neutralizing antibodies from vaccination to prevent SARS-CoV-2. SARS-CoV-2 mRNA vaccines should thus be recommended for both normal and suboptimal responders to conventional vaccines.https://www.mdpi.com/1999-4915/14/5/956coronavirus disease 2019severe acute respiratory syndrome coronavirus 2mRNA vaccineanti-spike antibodyneutralizing antibody |
| spellingShingle | Wataru Ogura Kouki Ohtsuka Sachiko Matsuura Takahiro Okuyama Satsuki Matsushima Satoko Yamasaki Hiroyuki Miyagi Kumiko Sekiguchi Hiroaki Ohnishi Takashi Watanabe Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination? Viruses coronavirus disease 2019 severe acute respiratory syndrome coronavirus 2 mRNA vaccine anti-spike antibody neutralizing antibody |
| title | Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination? |
| title_full | Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination? |
| title_fullStr | Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination? |
| title_full_unstemmed | Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination? |
| title_short | Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination? |
| title_sort | can individuals with suboptimal antibody responses to conventional antiviral vaccines acquire adequate antibodies from sars cov 2 mrna vaccination |
| topic | coronavirus disease 2019 severe acute respiratory syndrome coronavirus 2 mRNA vaccine anti-spike antibody neutralizing antibody |
| url | https://www.mdpi.com/1999-4915/14/5/956 |
| work_keys_str_mv | AT wataruogura canindividualswithsuboptimalantibodyresponsestoconventionalantiviralvaccinesacquireadequateantibodiesfromsarscov2mrnavaccination AT koukiohtsuka canindividualswithsuboptimalantibodyresponsestoconventionalantiviralvaccinesacquireadequateantibodiesfromsarscov2mrnavaccination AT sachikomatsuura canindividualswithsuboptimalantibodyresponsestoconventionalantiviralvaccinesacquireadequateantibodiesfromsarscov2mrnavaccination AT takahirookuyama canindividualswithsuboptimalantibodyresponsestoconventionalantiviralvaccinesacquireadequateantibodiesfromsarscov2mrnavaccination AT satsukimatsushima canindividualswithsuboptimalantibodyresponsestoconventionalantiviralvaccinesacquireadequateantibodiesfromsarscov2mrnavaccination AT satokoyamasaki canindividualswithsuboptimalantibodyresponsestoconventionalantiviralvaccinesacquireadequateantibodiesfromsarscov2mrnavaccination AT hiroyukimiyagi canindividualswithsuboptimalantibodyresponsestoconventionalantiviralvaccinesacquireadequateantibodiesfromsarscov2mrnavaccination AT kumikosekiguchi canindividualswithsuboptimalantibodyresponsestoconventionalantiviralvaccinesacquireadequateantibodiesfromsarscov2mrnavaccination AT hiroakiohnishi canindividualswithsuboptimalantibodyresponsestoconventionalantiviralvaccinesacquireadequateantibodiesfromsarscov2mrnavaccination AT takashiwatanabe canindividualswithsuboptimalantibodyresponsestoconventionalantiviralvaccinesacquireadequateantibodiesfromsarscov2mrnavaccination |